BioSpace News Archive

KRLS-017 is a reversible small molecule inhibitor of Cyclin Dependent Kinase 7. CDK7 has been implicated as a key regulator of both transcriptional addiction and cell cycle dysregulation in tumors and therefore represents an attractive target for therapeutic intervention across a broad range of solid tumors and hematologic malignancies.

Nutra Pharma Corporation, a biotechnology company marketing Nyloxin®, Pet Pain-Away™,Equine Pain-Away™ and Luxury Feet™ in the over-the-counter pain management market and which is also developing treatments for Multiple Sclerosis, Human Immunodeficiency Virus and Pain, is announcing their first agreement to act as a product formulator and contract manufacturer for an outside company, Avini Health.

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced it is presenting new data in scientific posters at the American Association for Cancer Research (AACR) Annual Meeting 2022, which will be held in-person and online, April 8-13, 2022.

Mammoth Biosciences, a biotech company building the next generation of CRISPR products to cure and detect disease, today announced the appointment of Elaine Sun as Chief Operating Officer (COO) and Chief Financial Officer (CFO).

Vaxxas, a clinical-stage biotechnology company commercializing a novel high-density microarray patch (HD-MAP) vaccination platform, today announced that The University of Texas at Austin has granted Vaxxas an exclusive license to a next-generation SARS-CoV-2 spike subunit vaccine (HexaPro), for vaccination using a patch.

Today, Hinge Health announced the results of the first 12-month outcome study demonstrating the long-term benefits of digital care for chronic musculoskeletal (MSK) pain. The peer-reviewed study, published in BMC Musculoskeletal Disorders, showed that pain was reduced by more than half (51%) and sustained over 12 months among Hinge Health participants.

RIBOMIC Inc., a clinical stage pharmaceutical company specializing in aptamer therapeutics (TOKYO:4591), today announced the results from the investigator sponsored trial (IST), TEMPURA, along with updated data from its TOFU and RAMEN studies with RBM-007, an investigational anti-fibroblast growth factor-2 aptamer, in wet age-related macular degeneration (wAMD).

ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that the company will be participating at the Maxim Group 2022 Virtual Growth Conference, taking place March 28-30, 2022.

Cosmos Holdings, Inc., an international pharmaceutical company with a proprietary line of nutraceuticals and distributor of branded and generic pharmaceuticals, nutraceuticals, OTC medications and medical devices, provides the following letter to its shareholders from CEO Greg Siokas:

Medical Database, Inc., an innovative provider of clinical laboratory and medical content, today announced the successful integration of its cutting-edge laboratory decision system, LDS®, with Epic.